Press coverage about Asterias Biotherapeutics (NYSE:AST) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Asterias Biotherapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.5169610165138 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Asterias Biotherapeutics (NYSE:AST) traded down 1.47% on Friday, hitting $3.35. The company had a trading volume of 103,165 shares. The stock’s 50-day moving average price is $3.33 and its 200 day moving average price is $3.34. The company’s market capitalization is $167.43 million. Asterias Biotherapeutics has a one year low of $2.83 and a one year high of $5.80.

Asterias Biotherapeutics (NYSE:AST) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $1.25 million. On average, analysts expect that Asterias Biotherapeutics will post ($0.61) EPS for the current fiscal year.

A number of research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Asterias Biotherapeutics in a report on Monday, October 2nd. Zacks Investment Research downgraded Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/asterias-biotherapeutics-ast-receives-media-impact-rating-of-0-15/1615725.html.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Insider Buying and Selling by Quarter for Asterias Biotherapeutics (NYSE:AST)

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.